ISSN: 2332-0877

Journal of Infectious Diseases & Therapy
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Research Article   
  • J Infect Dis Ther,
  • DOI: 10.4172/2332-0877.1000504

Predicting Fluconazole Drug-Drug Interactions Using a Physiologically-based Pharmacokinetic (PBPK) Model

Xue Li1, Keheng Wu1, Zhou Zhou1, Ranran Jia1, Youni Zhao1, Jingxi Li2 and Bo Liu2*
1Yinghan Pharmaceutical Technology (Shanghai) Co., Itd, Shanghai, China
2School of Chemical Engineering & Pharmacy, Wuhan Institute of Technology, Wuhan, China
*Corresponding Author : Dr. Bo Liu, School of Chemical Engineering & Pharmacy, Wuhan Institute of Technology, Wuhan, China, Email: liub@tcd.ie

Received Date: Jun 14, 2022 / Published Date: Jul 14, 2022

Abstract

Aim: Physiologically Based Pharmacokinetic (PBPK) model is developed to (1) simulate clinical trials involving the Drug-Drug Interactions (DDI) between fluconazole and drugs (substrates) metabolized primarily by CYP2C9 and CYP3A, and to (2) support dosing recommendations.

Methods: The plasma-concentration profiles were simulated in virtual individuals for each drug alone and in combination with fluconazole in B2O simulator. The effect of fluconazole on substrates was compared with published clinical data, and dose adjustment was carried out.

Results: The magnitude of inhibition tended to be more pronounced for substrates with predominant CYP3A4 metabolism, for example, lemborexant, than those with dual CYP3A4/2C9 metabolism. The dose of flurbiprofen was adjusted from 50 mg to 25 mg and 20 mg respectively, to counteract the DDI effects caused by fluconazole 200 mg/day and 400 mg/day.

Conclusion: The PBPK model established based on the mechanism of DDI and inhibitor’s effect on enzyme activity can reasonably simulate the effect of fluconazole on drug substrates mainly metabolized by CYP2C9, CYP3A or both.

Keywords: CYP2C9; CYP3A; Inhibitor; Fluconazole; Pharmacokinetic/pharmacodynamic model; Drug-drug interaction; Candidemia

Citation: Li X, Wu K, Zhou Z, Jia R, Zhao Y, et al. (2022) Predicting Fluconazole Drug-Drug Interactions Using a Physiologically-based Pharmacokinetic (PBPK) Model. J Infect Dis Ther 10: 504. Doi: 10.4172/2332-0877.1000504

Copyright: © 2022 Li X, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Top